Ohcanbohtosat - Cristina Helena Rama
- Čájehuvvo 1 - 6 / 6
-
1
Detecção sorológica de anti-HPV 16 e 18 e sua associação com os achados do papanicolaou em adolescentes e mulheres jovens Dahkki Cristina Helena Rama, Cecília Roteli-Martins, Sophie Derchain, Eliane Z. de Oliveira, José Mendes Aldrighi, Coríntio Mariani Neto
Almmustuhtton 2006Artigo -
2
Annual national direct and indirect cost estimates of the prevention and treatment of cervical cancer in Brazil Dahkki Hillegonda Maria Dutilh Novaes, Alexander Itria, Gulnar Azevedo e Silva, Ana Marli Christovam Sartori, Cristina Helena Rama, Patrícia Coelho de Soárez
Almmustuhtton 2015Artigo -
3
-
4
Awareness and knowledge of HPV, cervical cancer, and vaccines in young women after first delivery in São Paulo, Brazil - a cross-sectional study Dahkki Cristina Helena Rama, Luisa L. Villa, Sonia Pagliusi, Maria Antonieta Andreoli, Maria C Costa, Aline L Aoki, Adhemar Longatto‐Filho, José Eluf‐Neto
Almmustuhtton 2010Artigo -
5
Introduction of universal human papillomavirus vaccination of girls aged 11 years to the National Immunization Program in Brazil: a cost-effectiveness analysis Dahkki Hillegonda Maria Dutilh Novaes, Gulnar Azevedo e Silva, Alexander Itria, Cristina Helena Rama, Ana Marli Christovam Sartori, Patrícia Coelho de Soárez, Andrew Clark, Stephen Resch
Almmustuhtton 2014Artigo -
6
Modelo de Treinamento para Inserção de Dispositivos Intrauterinos Dahkki Brenda Diniz Rodrigues, Camila Fernanda Antunes Castanho Cavaleiro de Macêdo Loureiro, Mariseth Carvalho de Andrade, Suzana Rodrigues Ramos, Carolina Ribeiro Mainardi, Cristina Helena Rama, Nara Macedo Botelho
Almmustuhtton 2019Artigo
Ohcanreaiddut:
Laktáseaddji fáttát
Internal medicine
Medicine
Cancer
Cervical cancer
Environmental health
Gynecology
Population
Human papillomavirus
Immunology
Nursing
Public health
Vaccination
Accounting
Activity-based costing
Art
Biology
Business
Cohort
Cost driver
Cost effectiveness
Cost-effectiveness analysis
Cost–benefit analysis
Cross-sectional study
Demography
Disability-adjusted life year
Disease burden
Economic cost
Economic growth
Economics
Family medicine